Multiple companies, including AbbVie, Amgen, and Alnylam, saw analyst target prices adjusted on July 13, 2026, including raises and cuts.

The entities involved

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
• Amgen →

  American multinational biopharmaceutical company

  • Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
  • Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
• Alnylam Pharmaceuticals →

  biopharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Sun 17:03

Related events

• HSBC raised its price target to $315, and the FDA issued a complete response letter regarding trenibotE.Sep 10
• Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.Aug 5